Mechelen, Belgium;
26 October 2007 - Galapagos NV (Euronext & LSE: GLPG)
announced today that its Board of Directors has created
and offered 114,100 warrants under a new warrant plan for
Galapagos employees.
On 25 October 2007 the Board
of Directors of Galapagos approved the “Warrant Plan
2007 RMV” within the framework of the authorized capital.
Since its inception in 1999, Galapagos has used warrant
plans to allow personnel and management to be involved in
the company’s growth and development. Under this new
warrant plan 114,100 warrants were created and offered to
employees of Galapagos’ affiliate in Romainville (France).
The warrants have an exercise period of eight years starting
as of the date of the offer. They are not transferable and
cannot be exercised prior to the end of the third calendar
year after the year in which they were granted to a warrant
holder. Each warrant gives the right to subscribe to one
new Galapagos share. Should the warrants be exercised, Galapagos
will apply for the listing of the resulting new shares on
a regulated stock market. The warrants as such will not
be admitted to listing on any stock market.
About Galapagos
Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam,
GLPGA; London AiM: GLPG) is a drug discovery company with
pre-clinical programs in bone and joint diseases and cachexia.
Its division BioFocus DPI offers a full suite of target-to-drug
discovery products and services to pharmaceutical and biotech
companies, encompassing target discovery and validation,
screening and drug discovery through to delivery of pre-clinical
candidates. BioFocus DPI also provides adenoviral reagents
for rapid identification and validation of novel drug targets,
compound libraries for drug screening as well as chemogenomics
and ADMET database products to select targets and compounds.
Galapagos currently employs 460 people and operates facilities
in seven countries, with global headquarters in Mechelen,
Belgium. More information about Galapagos and BioFocus DPI
can be found at
www.glpg.com and
www.biofocusdpi.com.
CONTACT
Galapagos NV
Onno van de Stolpe, CEO
Tel: +31 6 2909 8028
ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words “believes,”
“anticipates,” “expects,” “intends,”
“plans,” “seeks,” “estimates,”
“may,” “will,” “could,”
“stands to,” and “continues,” as
well as similar expressions. Such forward-looking statements
may involve known and unknown risks, uncertainties and other
factors which might cause the actual results, financial
condition, performance or achievements of Galapagos, or
industry results, to be materially different from any historic
or future results, financial conditions, performance or
achievements expressed or implied by such forward-looking
statements. Given these uncertainties, the reader is advised
not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only
as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement
is based, unless required by law or regulation.
